OBJECTIVE: Undesirable mictional problems caused by a BPH - benign prostatic hypertrophy - have been found in 20 to 25 % of the male population over 50 years old. This condition can thus be considered as a public health problem that offers many aspects in terms of diagnosis, therapeutics or economics. METHOD: Using a follow-up cohort study, we isolated two groups presenting a recently diagnosed BPH: the first patient population was kept under medical supervision (n=101) versus a second patient population undergoing treatment with Serenoa Repens (n=112) RESULTS : For the patients under medical supervision, the IPSS score was respectively 11.8 (5.7) and 10.9 (6.7) upon patient inclusion and after 6 months. This difference is not statistically significant. However, for the patients treated with Serenoa Repens, the IPSS score was respectively 14.3 (6.6) and 11.9 (5.7) upon patient inclusion and after 6 months. The noted difference is statistically significant (p<0.0001). CONCLUSION: Patients suffering from a recently diagnosed BPH and treated with Serenoa Repens thus showed a statistically significant improvement as demonstrated by the IPSS score.